scispace - formally typeset
K

Koji Koike

Researcher at Kyushu University

Publications -  14
Citations -  1240

Koji Koike is an academic researcher from Kyushu University. The author has contributed to research in topics: Y box binding protein 1 & Gene. The author has an hindex of 10, co-authored 14 publications receiving 1213 citations.

Papers
More filters
Journal Article

A Canalicular Multispecific Organic Anion Transporter (cMOAT) Antisense cDNA Enhances Drug Sensitivity in Human Hepatic Cancer Cells

TL;DR: Results suggest that cMOAT levels are inversely correlated with those of glutathione, and that c MOAT and its related genes may be involved in the sensitivity of cells to certain anticancer agents.
Journal Article

Role of the Human Y Box-binding Protein YB-1 in Cellular Sensitivity to the DNA-damaging Agents Cisplatin, Mitomycin C, and Ultraviolet Light

TL;DR: YB-1 may protect cells from the cytotoxic effects of agents that induce cross-linking of DNA, suggesting a novel function of this ancestor DNA-binding protein.
Journal ArticleDOI

Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene

TL;DR: YB-1 is directly involved in MDR1 gene activation in response to genotoxic stress, indicating that an inverted CCAAT box (Y-box) might be a critical cis-regulatory element regulating UV or drug-induced MDR 1 gene expression.
Journal ArticleDOI

Nuclear translocation of the y-box binding protein by ultraviolet irradiation

TL;DR: YB‐1 is translocated into the nucleus by UV irradiation, possibly through a protein kinase C‐mediated signal transduction pathway, and the C‐terminal region of YB‐ 1 might be important for cytoplasmic retention of Yb‐1.
Journal ArticleDOI

Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1.

TL;DR: This study investigated whether chemosensitising agents of P-glycoprotein-mediated multidrug resistance such as verapamil, a biscoclaurine alkaloid (cepharanthine), and a dihydropyridine analogue (NIK250) could also reverse multidrog resistance in human glioma cells, and reversed drug resistance to vincristine, etoposide and doxorubicin.